BACKGROUND: Medical diagnosis and prognosis using machine learning methods is usually represented as a supervised classification problem, where a model is built to distinguish "normal" from "abnormal" cases. If cases are available from only one class, this approach is not feasible. OBJECTIVE: To evaluate the performance of classification via outlier detection by one-class support vector machines (SVMs) as a means of identifying abnormal cases in the domain of melanoma prognosis. METHODS: Empirical evaluation of one-class SVMs on a data set for predicting the presence or absence of metastases in melanoma patients, and comparison with regular SVMs and artificial neural networks. RESULTS: One-class SVMs achieve an area under the ROC curve (AUC) of 0.71; two-class algorithms achieve AUCs between 0.5 and 0.84, depending on the available number of cases from the minority class. CONCLUSION: One-class SVMs offer a viable alternative to two-class classification algorithms if class distribution is heavily imbalanced.
BACKGROUND: Medical diagnosis and prognosis using machine learning methods is usually represented as a supervised classification problem, where a model is built to distinguish "normal" from "abnormal" cases. If cases are available from only one class, this approach is not feasible. OBJECTIVE: To evaluate the performance of classification via outlier detection by one-class support vector machines (SVMs) as a means of identifying abnormal cases in the domain of melanoma prognosis. METHODS: Empirical evaluation of one-class SVMs on a data set for predicting the presence or absence of metastases in melanomapatients, and comparison with regular SVMs and artificial neural networks. RESULTS: One-class SVMs achieve an area under the ROC curve (AUC) of 0.71; two-class algorithms achieve AUCs between 0.5 and 0.84, depending on the available number of cases from the minority class. CONCLUSION: One-class SVMs offer a viable alternative to two-class classification algorithms if class distribution is heavily imbalanced.
Authors: J M Auge; R Molina; X Filella; E Bosch; M Gonzalez Cao; S Puig; J Malvehy; T Castel; A M Ballesta Journal: Anticancer Res Date: 2005 May-Jun Impact factor: 2.480
Authors: M González Cao; J M Auge; R Molina; R Martí; C Carrera; T Castel; R Vilella; C Conill; M Sánchez; J Malvehy; S Puig Journal: Anticancer Res Date: 2007 Jan-Feb Impact factor: 2.480